Summit Therapeutics PLC teams up with cTAP as it looks to accelerate development of its DMD drug: "Drug discoverer Summit Therapeutics PLC (LON:SUMM; NASDAQ:SMMT) has teamed up with the Collaborative Trajectory Analysis Project to try and accelerate the development of its lead Duchenne muscular dystrophy candidate.
Summit’s utrophin modulator for the treatment of DMD – ezutromid – is currently in a phase II clinical trial, with data from the 48-week study expected in the third quarter of 2018.
But the dual-listed firm hopes that by partnering with cTAP, it can potentially adapt and improve the overall clinical process."
'via Blog this'
No comments:
Post a Comment